Novo Nodrisk stock dips on aggressive odder to buy Metsera, ’reckless’ says Pfizer By Investing.com
Update: 2025-10-30
Description
Novo Nordisk makes a bold move by offering $8 billion for Metsera, surpassing Pfizer's bid. This aggressive offer, valued at $56.50 per share, could intensify competition in the obesity drug market. Pfizer responds harshly, accusing Novo of attempting to stifle competition and violating the law. The situation escalates, with Pfizer's shares dropping and the potential for a legal battle or bidding war.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
